Bayesian methods for the design and analysis of noninferiority trials

被引:16
|
作者
Gamalo-Siebers, Margaret [1 ]
Gao, Aijun [2 ]
Lakshminarayanan, Mani [3 ]
Liu, Guanghan [4 ]
Natanegara, Fanni [5 ]
Railkar, Radha [3 ]
Schmidli, Heinz [6 ]
Song, Guochen [7 ]
机构
[1] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA
[2] InVent Hlth Clin, Princeton, NJ USA
[3] Pfizer Inc, Biotechnol Clin Dev Stat, Collegeville, PA 19426 USA
[4] Merck Sharp & Dohme Corp, N Wales, PA USA
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Novartis Pharma AG, Basel, Switzerland
[7] Quintiles, Durham, NC USA
关键词
Bayesian inference; clinical trial; meta-analysis; noninferiority; ACTIVE-CONTROL TRIALS; SAMPLE-SIZE CALCULATIONS; NON-INFERIORITY TRIALS; CLINICAL-TRIALS; HISTORICAL INFORMATION; STATISTICAL-METHODS; PLACEBO; PROPORTIONS; COMBINATION; HYPOTHESIS;
D O I
10.1080/10543406.2015.1074920
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The gold standard for evaluating treatment efficacy of a medical product is a placebo-controlled trial. However, when the use of placebo is considered to be unethical or impractical, a viable alternative for evaluating treatment efficacy is through a noninferiority (NI) study where a test treatment is compared to an active control treatment. The minimal objective of such a study is to determine whether the test treatment is superior to placebo. An assumption is made that if the active control treatment remains efficacious, as was observed when it was compared against placebo, then a test treatment that has comparable efficacy with the active control, within a certain range, must also be superior to placebo. Because of this assumption, the design, implementation, and analysis of NI trials present challenges for sponsors and regulators. In designing and analyzing NI trials, substantial historical data are often required on the active control treatment and placebo. Bayesian approaches provide a natural framework for synthesizing the historical data in the form of prior distributions that can effectively be used in design and analysis of a NI clinical trial. Despite a flurry of recent research activities in the area of Bayesian approaches in medical product development, there are still substantial gaps in recognition and acceptance of Bayesian approaches in NI trial design and analysis. The Bayesian Scientific Working Group of the Drug Information Association provides a coordinated effort to target the education and implementation issues on Bayesian approaches for NI trials. In this article, we provide a review of both frequentist and Bayesian approaches in NI trials, and elaborate on the implementation for two common Bayesian methods including hierarchical prior method and meta-analytic-predictive approach. Simulations are conducted to investigate the properties of the Bayesian methods, and some real clinical trial examples are presented for illustration.
引用
下载
收藏
页码:823 / 841
页数:19
相关论文
共 50 条
  • [1] Bayesian methods for design and analysis of safety trials
    Price, Karen L.
    Xia, H. Amy
    Lakshminarayanan, Mani
    Madigan, David
    Manner, David
    Scott, John
    Stamey, James D.
    Thompson, Laura
    PHARMACEUTICAL STATISTICS, 2014, 13 (01) : 13 - 24
  • [2] Bayesian Design of Noninferiority Trials for Medical Devices Using Historical Data
    Chen, Ming-Hui
    Ibrahim, Joseph G.
    Lam, Peter
    Yu, Alan
    Zhang, Yuanye
    BIOMETRICS, 2011, 67 (03) : 1163 - 1170
  • [3] BAYESIAN APPROACH TO NONINFERIORITY TRIALS FOR PROPORTIONS
    Gamalo, Mark A.
    Wu, Rui
    Tiwari, Ram C.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (05) : 902 - 919
  • [4] Design and Interpretation of Noninferiority Trials
    Vach, Werner
    Gladstone, Beryl Primrose
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 (08) : 1216 - 1216
  • [5] Design and Interpretation of Noninferiority Trials
    Ricky Daniel Turgeon
    Emma K. Reid
    Daniel Christopher Rainkie
    Journal of General Internal Medicine, 2018, 33 : 1215 - 1215
  • [6] DESIGN OF CLINICAL-TRIALS WITH BAYESIAN METHODS
    ACHCAR, JA
    BIOMETRICS, 1984, 40 (01) : 272 - 272
  • [7] Bayesian Design of Superiority Trials: Methods and Applications
    Yuan, Wenlin
    Chen, Ming-Hui
    Zhong, John
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2022, 14 (04): : 433 - 443
  • [8] Considerations for Design and Data Analysis of Noninferiority/Superiority Cardiovascular Trials
    Quan, Hui
    Li, Mingyu
    Zhao, Peng-Liang
    Cho, Meehyung
    Zhang, Ji
    Wu, Yujun
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (01) : 239 - 260
  • [9] Challenges in the Design and Interpretation of Noninferiority Trials
    Mauri, Laura
    D'Agostino, Ralph B., Sr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (14): : 1357 - 1367
  • [10] Design issues in noninferiority/equivalence trials
    Hwang, IK
    Morikawa, T
    DRUG INFORMATION JOURNAL, 1999, 33 (04): : 1205 - 1218